| First Author | Liang C | Year | 2019 |
| Journal | Nat Commun | Volume | 10 |
| Issue | 1 | Pages | 4579 |
| PubMed ID | 31594926 | Mgi Jnum | J:281963 |
| Mgi Id | MGI:6378047 | Doi | 10.1038/s41467-019-12163-z |
| Citation | Liang C, et al. (2019) HIF1alpha inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis. Nat Commun 10(1):4579 |
| abstractText | Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by progressive bone erosion. Leflunomide is originally developed to suppress inflammation via its metabolite A77 1726 to attenuate bone erosion. However, distinctive responsiveness to Leflunomide is observed among RA individuals. Here we show that Leflunomide exerts immunosuppression but limited efficacy in RA individuals distinguished by higher serum C-reactive protein (CRP(Higher), CRP(H)), whereas the others with satisfactory responsiveness to Leflunomide show lower CRP (CRP(Lower), CRP(L)). CRP inhibition decreases bone erosion in arthritic rats. Besides the immunomodulation via A77 1726, Leflunomide itself induces AHR-ARNT interaction to inhibit hepatic CRP production and attenuate bone erosion in CRP(L) arthritic rats. Nevertheless, high CRP in CRP(H) rats upregulates HIF1alpha, which competes with AHR for ARNT association and interferes Leflunomide-AHR-CRP signaling. Hepatocyte-specific HIF1alpha deletion or a HIF1alpha inhibitor Acriflavine re-activates Leflunomide-AHR-CRP signaling to inhibit bone erosion. This study presents a precision medicine-based therapeutic strategy for RA. |
